MDT

84.21

-0.14%↓

VEEV

226.67

-0.19%↓

A

106.17

-0.03%↓

WBA

11

-0.09%↓

CHE

555.99

+0.34%↑

MDT

84.21

-0.14%↓

VEEV

226.67

-0.19%↓

A

106.17

-0.03%↓

WBA

11

-0.09%↓

CHE

555.99

+0.34%↑

MDT

84.21

-0.14%↓

VEEV

226.67

-0.19%↓

A

106.17

-0.03%↓

WBA

11

-0.09%↓

CHE

555.99

+0.34%↑

MDT

84.21

-0.14%↓

VEEV

226.67

-0.19%↓

A

106.17

-0.03%↓

WBA

11

-0.09%↓

CHE

555.99

+0.34%↑

MDT

84.21

-0.14%↓

VEEV

226.67

-0.19%↓

A

106.17

-0.03%↓

WBA

11

-0.09%↓

CHE

555.99

+0.34%↑

Search

Bristol-Myers Squibb Co.

Abierto

SectorSalud

47.8 -1.42

Resumen

Variación precio

24h

Actual

Mínimo

46.95

Máximo

48.84

Métricas clave

By Trading Economics

Ingresos

-1.1B

76M

Ventas

442M

12B

P/B

Media del Sector

14.05

57.333

BPA

1.67

Rentabilidad por dividendo

5.04

Margen de beneficio

0.616

Empleados

34,100

EBITDA

-1.9B

2.6B

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 meses

+18.22% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

5.04%

2.63%

Fecha Próximo Dividendo

1 may 2025

Próxima Fecha de Ex Dividendo

4 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-21B

100B

Apertura anterior

49.22

Cierre anterior

47.8

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

Bristol-Myers Squibb Co. Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

24 abr 2025, 11:32 UTC

Ganancias

Bristol Myers Squibb Swings to Profit in 1Q, Increases Fiscal Year Guidance

11 mar 2025, 10:13 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

11 mar 2025, 10:13 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

24 abr 2025, 21:24 UTC

Principales Noticias
Ganancias

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 abr 2025, 14:15 UTC

Principales Noticias
Ganancias

Bristol Myers Squibb Shares Sink Despite Better-than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 abr 2025, 12:37 UTC

Charlas de Mercado
Ganancias

Bristol Myers Squibb Raises Guidance, But Any Pharma-Sector Tariffs Could be a Drag -- Market Talk

24 abr 2025, 11:17 UTC

Ganancias

Bristol Myers Squibb Swings to Profit in 1Q, Increases FY Guidance

24 abr 2025, 11:13 UTC

Principales Noticias
Ganancias

Bristol Myers Squibb Posts Better-than-Expected Earnings, Raises Full-Year Guidance -- Barrons.com

24 abr 2025, 10:59 UTC

Ganancias

Bristol Myers Squibb: Raised 1Q Rev Outlook Reflecting Strong Performance of Growth Portfolio, Better-Than-Expected 1Q Legacy Portfolio Sales and Favorable Impact of About $500M Related to Forex Rates >BMY

24 abr 2025, 10:59 UTC

Ganancias

Bristol Myers Squibb Latest 1Q Includes Acquired IPRD Charge of $188M >BMY

24 abr 2025, 10:59 UTC

Ganancias

Bristol Myers Squibb 1Q U.S. Revenue Fell 7% to $7.87B >BMY

24 abr 2025, 10:59 UTC

Ganancias

Bristol Myers Squibb: Guidance Revisions Include Estimated Impact of Current Tariffs on U.S. Products Shipped to China, but Do Not Account for Any Potential Pharmaceutical Sector Tariffs >BMY

24 abr 2025, 10:59 UTC

Ganancias

Bristol Myers Squibb 1Q Growth Portfolio Revenue Rose 16% to $5.56B >BMY

24 abr 2025, 10:59 UTC

Ganancias

Bristol Myers Squibb: Growth Portfolio Revenue Increase Primarily Driven by Opdivo, Breyanzi, Reblozyl and Camzyos and Reflects Strong Early U.S. Launch of Cobenfy >BMY

24 abr 2025, 10:59 UTC

Ganancias

Bristol Myers Squibb 1Q Adjusted Gross Margin 73.1% >BMY

24 abr 2025, 10:59 UTC

Ganancias

Bristol Myers Squibb 1Q International Revenue Fell 2% to $3.33B >BMY

24 abr 2025, 10:59 UTC

Ganancias

Bristol Myers Squibb: Legacy Portfolio Rev Decline Driven by Continued Generic Impact on Revlimid, Pomalyst, Sprycel and Abraxane, as Well as Impact From U.S. Medicare Part D Redesign >BMY

24 abr 2025, 10:59 UTC

Ganancias

Bristol Myers Squibb 1Q Legacy Portfolio Rev Fell 20% to $5.64B >BMY

24 abr 2025, 10:59 UTC

Ganancias

Bristol Myers Squibb 1Q Adj EPS $1.80 >BMY

24 abr 2025, 10:59 UTC

Ganancias

Bristol Myers Squibb Raises 2025 View To Rev $45.8B-$46.8B Vs Prior View $45.5B >BMY

24 abr 2025, 10:59 UTC

Ganancias

Bristol Myers Squibb 1Q Gross Margin 72.9% >BMY

24 abr 2025, 10:59 UTC

Ganancias

Bristol Myers Squibb Raises 2025 View To Adj EPS $6.70-Adj EPS $7.00 Vs Prior View $6.55-$6.85 >BMY

24 abr 2025, 10:59 UTC

Ganancias

Bristol Myers Squibb 1Q Rev $11.2B >BMY

24 abr 2025, 10:59 UTC

Ganancias

Bristol Myers Squibb 1Q EPS $1.20 >BMY

24 abr 2025, 10:59 UTC

Ganancias

Bristol-Myers Squibb 1Q Adj EPS $1.80 >BMY

24 abr 2025, 10:59 UTC

Ganancias

Bristol-Myers Squibb 1Q Rev $11.2B >BMY

24 abr 2025, 10:59 UTC

Ganancias

Bristol-Myers Squibb 1Q Net $2.46B >BMY

24 abr 2025, 10:59 UTC

Ganancias

Bristol-Myers Squibb Sees FY Adj EPS $6.70-Adj EPS $7.00 >BMY

24 abr 2025, 10:59 UTC

Ganancias

Bristol-Myers Squibb 1Q EPS $1.20 >BMY

14 mar 2025, 09:30 UTC

Principales Noticias

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

Comparación entre iguales

Cambio de precio

Bristol-Myers Squibb Co. Esperado

Precio Objetivo

By TipRanks

18.22% repunte

Estimación a 12 meses

Media 57.56 USD  18.22%

Máximo 70 USD

Mínimo 36 USD

De acuerdo con 19 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Bristol-Myers Squibb Co. Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

19 ratings

5

Comprar

13

Mantener

1

Vender

Puntuación técnica

By Trading Central

47.54 / 48.82Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Strong Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.